344 related articles for article (PubMed ID: 23773063)
1. Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission.
Mohamed NV; Herrou T; Plouffe V; Piperno N; Leclerc N
Eur J Neurosci; 2013 Jun; 37(12):1939-48. PubMed ID: 23773063
[TBL] [Abstract][Full Text] [Related]
2. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
3. Of rodents and men: the mysterious interneuronal pilgrimage of misfolded protein tau in Alzheimer’s disease.
Levarska L; Zilka N; Jadhav S; Neradil P; Novak M
J Alzheimers Dis; 2013; 37(3):569-77. PubMed ID: 23948940
[TBL] [Abstract][Full Text] [Related]
4. Minimalistic in vitro systems for investigating tau pathology.
Hallinan GI; Pitera AP; Patel P; West J; Deinhardt K
J Neurosci Methods; 2019 May; 319():69-76. PubMed ID: 30278185
[TBL] [Abstract][Full Text] [Related]
5. First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.
Smolek T; Jadhav S; Brezovakova V; Cubinkova V; Valachova B; Novak P; Zilka N
Mol Neurobiol; 2019 Jan; 56(1):621-631. PubMed ID: 29770957
[TBL] [Abstract][Full Text] [Related]
6. [Significance of tau in the development of Alzheimer's disease].
Takashima A
Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
[TBL] [Abstract][Full Text] [Related]
7. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice.
Baker S; Polanco JC; Götz J
J Alzheimers Dis; 2016 Oct; 54(3):1207-1217. PubMed ID: 27567840
[TBL] [Abstract][Full Text] [Related]
9. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
10. The Neurotoxic Role of Extracellular Tau Protein.
Sebastián-Serrano Á; de Diego-García L; Díaz-Hernández M
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584657
[TBL] [Abstract][Full Text] [Related]
11. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.
Ishihara T; Zhang B; Higuchi M; Yoshiyama Y; Trojanowski JQ; Lee VM
Am J Pathol; 2001 Feb; 158(2):555-62. PubMed ID: 11159192
[TBL] [Abstract][Full Text] [Related]
12. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
[TBL] [Abstract][Full Text] [Related]
13. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
15. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?
Grinberg LT; Rüb U; Ferretti RE; Nitrini R; Farfel JM; Polichiso L; Gierga K; Jacob-Filho W; Heinsen H;
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):406-16. PubMed ID: 19508444
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
[TBL] [Abstract][Full Text] [Related]
17. Spreading of Pathology in Alzheimer's Disease.
Lv ZY; Tan CC; Yu JT; Tan L
Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
[TBL] [Abstract][Full Text] [Related]
18. Neurons associated with aggrecan-based perineuronal nets are protected against tau pathology in subcortical regions in Alzheimer's disease.
Morawski M; Brückner G; Jäger C; Seeger G; Arendt T
Neuroscience; 2010 Sep; 169(3):1347-63. PubMed ID: 20497908
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions.
Togo T; Akiyama H; Iseki E; Uchikado H; Kondo H; Ikeda K; Tsuchiya K; de Silva R; Lees A; Kosaka K
Acta Neuropathol; 2004 Jun; 107(6):504-8. PubMed ID: 15024583
[TBL] [Abstract][Full Text] [Related]
20. Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies.
Annadurai N; De Sanctis JB; Hajdúch M; Das V
Exp Neurol; 2021 Sep; 343():113756. PubMed ID: 33989658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
